Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hematopoietic progenitor cell marrow therapy - Ossium Health

Next Previous
X
Search
Drug Profile

Hematopoietic progenitor cell marrow therapy - Ossium Health

Alternative Names: HPC marrow

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ossium Health
  • Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Transplant rejection
  • Phase I/II Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Preclinical Graft-versus-host disease

Most Recent Events

  • 10 May 2024 Ossium Health intends to initiate HOPE (HPC Offered for PRESERVE Expansion) program for patients with Acute myeloid leukemia that need an allogeneic bone marrow transplant but are ineligible to participate in Ossium’s active clinical study (PRESERVE I)
  • 10 May 2024 Ossium Health plans to initiate a long-term phase II trial in Acute myeloid leukaemia (PRESERVE II)
  • 28 Mar 2024 Preclinical trials in Graft-versus-host disease in USA (Parenteral) (Ossium Health pipeline; March 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top